Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

NCT07095465 is registered in ClinicalTrials.gov with ACADIA Pharmaceuticals Inc. as lead sponsor.

NCT NCT07095465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07095465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
Lead sponsor
ACADIA Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
November 14, 2025
Completion date
March 31, 2029
Enrollment
126 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

lewy body dementia psychosis